CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Total revenues	$ 0	$ 482
Costs and Expenses:
Costs of goods sold	0	47
Research and development	58,172	28,843
Sales and marketing	7,881	2,366
General and administrative	13,595	6,854
Total costs and expenses	79,648	38,110
Operating loss	(79,648)	(37,628)
Changes in fair market value of warrant liabilities	0	9,835
Interest expense	(9,959)	(10,900)
Interest and other income	2,203	1,130
Insurance reimbursement	0	1,930
Foreign currency transaction gain, net	0	75
Loss before income tax	(87,404)	(35,558)
Income tax (expense) benefit	0	0
Net loss	(87,404)	(35,558)
Net loss attributable to noncontrolling interest	(67)	(12)
Net loss attributable to Immunomedics, Inc. stockholders	$ (87,337)	$ (35,546)
Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted) (in usd per share)	$ (0.46)	$ (0.21)
Weighted average shares used to calculated loss per common share (basic and diluted) (in shares)	191,052	166,054
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	$ (9)	$ (66)
Unrealized (loss) gain on securities available for sale	(200)	10
Other comprehensive loss, net of tax:	(209)	(56)
Comprehensive loss	(87,613)	(35,614)
Comprehensive loss attributable to noncontrolling interest	(67)	(12)
Comprehensive loss attributable to Immunomedics, Inc. stockholders	(87,546)	(35,602)
Product sales
Total revenues	0	450
License fee and other revenues
Total revenues	0	15
Research and development
Total revenues	$ 0	$ 17